Ab Science Paris (ABSCF) 14.2900 $ABSCF
Global B-Cell Chronic Lymphocytic Leukemia Pipeline Review, H2 2015 - 21 Companies & 31 Drug Profiles
M2 - Wed Oct 07, 3:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jtsp4f/bcell_chronic) has announced the addition of the "B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - AbbVie Inc. - Advancell - Amgen Inc. - BioNovion B.V. - Celgene Corporation - Dynavax Technologies Corporation - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Formula Pharmaceuticals, Inc. - iDD biotech SAS - Immunomedics, Inc. - Johnson & Johnson - Juno Therapeutics Inc. - Nippon Shinyaku Co., Ltd. - Noxxon Pharma AG - Ono Pharmaceutical Co., Ltd. - Regeneron Pharmaceuticals, Inc. - SBI Biotech Co., Ltd. - TheraMAB LLC - Vivia Biotech, S.L. Drug Profiles - 202-b - AB-8779 - acadesine - alemtuzumab biosimilar - AMG-319 - bafetinib - BION-1301 - Cell Therapy for Hematological Malignancies - Cell Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Cell Therapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Cell Therapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Cell Therapy to Target CD16 for CLL and NHL - Cell Therapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Cell Therapy to Target CD19 for Cancer - Cell Therapy to Target CD19 for Oncology - Cell Therapy to Target CD23 for B-Cell Chronic Lymphocytic Leukemia - E-7449 - GNKS-356 - IDD-001 - IDD-002 - ilorasertib - JNJ-64052781 - lenalidomide - MAT-303 - olaptesed pegol - ONO-4059 - REGN-1979 - SD-101 - TAB-08 - tocilizumab - Vivia-009 For more information visit http://www.researchandmarkets.com/research/jt...ll_chronic
DVAX: 23.86 (+0.39), JNJ: 95.37 (+0.29), IMMU: 2.17 (+0.12), AMGN: 149.59 (-0.31), JUNO: 48.64 (+0.84), ABBV: 55.64 (-0.40), REGN: 503.92 (+12.71), CELGZ: 1.74 (+0.04)
Gastric Cancer - Pipeline Review, H2 2015 Featuring Over 100 Companies
M2 - Mon Oct 05, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lhb64g/gastric_cancer) has announced the addition of the "Gastric Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - 30 of the 100 Companies - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Azaya Therapeutics Incorporated - Basilea Pharmaceutica AG - Bayer AG - BioMarin Pharmaceutical Inc. - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - cCAM Biotherapeutics Ltd. - Celgene Corporation - Celldex Therapeutics, Inc. - Cellectar Biosciences, Inc. - Celltrion, Inc. - Celon Pharma Sp. z o.o. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Chugai Pharmaceutical Co., Ltd. - Curaxys, S.L. For more information visit http://www.researchandmarkets.com/research/lh...ric_cancer
CLRB: 2.01 (+0.03), ADXS: 11.07 (+0.83), BMRN: 102.69 (+1.97), CERU: 3.65 (+0.07), AMBX: (), CLDX: 12.80 (+1.06), AMGN: 149.59 (-0.31), BMY: 61.44 (+0.93), AZN: 32.23 (-0.16), AVEO: 1.27 (+0.05), ABBV: 55.64 (-0.40), CELGZ: 1.74 (+0.04)
Global Germ Cell Tumors Pipeline Review H2 2015 - 8 Companies & 11 Drug Profiles
M2 - Mon Oct 05, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/444kf4/germ_cell_tumors) has announced the addition of the "Germ Cell Tumors - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Germ Cell Tumors, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Germ Cell Tumors and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - ArQule, Inc. - Astex Pharmaceuticals, Inc. - GlaxoSmithKline Plc - MediGene AG - Merck & Co., Inc. - Novartis AG - Philogen S.p.A. - Sanofi Drug Profiles - cabazitaxel - Cell Therapy 1 for Oncology - (dabrafenib mesylate trametinib dimethyl sulfoxide) - G-207 - guadecitabine - pembrolizumab - ribociclib - Small Molecule to Antagonize KIT816 for Aggressive Mastocytosis, Seminoma and AML - Small Molecules to Inhibit Tubulin for Oncology - Tetravil - tivantinib For more information visit http://www.researchandmarkets.com/research/44...ell_tumors
MRK: 50.95 (-0.07), ARQL: 2.04 (+0.05), GSK: 40.22 (+0.06), NVS: 91.90 (-0.71)
AB Science announces cessation of its rheumatoid arthritis study in order to focus on clinical studies with a probability of success greater than 50%
GlobeNewswire - Mon Sep 21, 11:07AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces today the decision to stop the phase 3 study of masitinib in rheumatoid arthritis in order to streamline its studies portfolio. This decision has been made following a futility test, conducted by the external Data and Safety Monitoring Board (DSMB), showing that the probability of success on the primary endpoint was below 50% for this study, including the resampling option.
AB: 26.72 (-0.07)
AB Science: Masitinib Receives Orphan Drug Designation for Stomach Cancer from FDA
GlobeNewswire - Wed Sep 16, 11:07AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug designation for masitinib in the treatment of esophagogastric adenocarcinoma.
AB: 26.72 (-0.07)
Global Secondary Progressive Multiple Sclerosis (SPMS) Pipeline Review, H2 2015 - 12 Companies & 17 Drug Profiles
M2 - Tue Sep 08, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j7vt6v/secondary) has announced the addition of the "Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - Biogen, Inc. - Daval International Limited - Genzyme Corporation - Glialogix, Inc. - Immune Response BioPharma, Inc. - Innate Immunotherapeutics Limited - Kyorin Pharmaceutical Co., Ltd. - MedDay - Merck KGaA - Novartis AG - Opexa Therapeutics, Inc. Drug Profiles - Aimspro - ApE - ATXMS-1467 - biotin - DC-TAB - GLX-1112 - GZ-402668 - ibudilast - imilecleucel-t - interferon beta-1b - IR-902 - masitinib - MIS-416 - natalizumab - opicinumab - OSX-110 - siponimod For more information visit http://www.researchandmarkets.com/research/j7vt6v/secondary
OPXA: 3.20 (-0.08), NVS: 91.90 (-0.71)
AB Science announces successful futility test for masitinib in c-Kit mutated metastatic melanoma
GlobeNewswire - Tue Jul 21, 11:32AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), today announced the successful non futility analysis related to the masitinib phase 3 trial in metastatic melanoma, carrying a mutation in the juxta membrane domain of c-Kit. Based on these results, the Independent Data Safety Monitoring Committee (IDMC) has recommended continuation of the study.
AB: 26.72 (-0.07)
AB Science announces initiation of an adaptive design phase 2/3 study with masitinib in patients with refractory metastatic ovarian cancer
GlobeNewswire - Wed Jul 15, 11:12AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the initiation of a seamless adaptive design phase 2/3 study to evaluate the safety and efficacy of masitinib in combination with gemcitabine in patients with refractory advanced or metastatic epithelial ovarian cancer.
AB: 26.72 (-0.07)
AB Science: the Data and Safety Monitoring Board recommends continuation of three phase 2 studies
GlobeNewswire - Thu Jul 02, 11:21AM CDT
The Data and Safety Monitoring Board recommends continuation of three phase 2 studies assessing masitinib in relapsing liver cancer, breast cancer, and head and neck cancer based on safety and efficacy data
AB: 26.72 (-0.07)
AB Science: Update on phase 1/2 program with masitinib in solid tumors
GlobeNewswire - Thu Jun 25, 12:52PM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), presents an update of its masitinib phase 1/2 program in solid tumors.
AB: 26.72 (-0.07)
AB Science: Independent Publication from experts highlights the potential of masitinib in Alzheimer's disease
GlobeNewswire - Thu May 21, 12:56PM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announces the publication of a wide-ranging independent review article entitled 'Masitinib for the treatment of mild to moderate Alzheimer's disease' in the peer-reviewed journal Expert Review of Neurotherapeutics.
AB: 26.72 (-0.07)
AB Science announces that three clinical abstracts will be presented at the 2015 ASCO annual meeting
GlobeNewswire - Mon May 18, 11:43AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announced that the three abstracts reporting on phase 2 studies of masitinib in metastatic colorectal cancer, metastatic esophagogastric adenocarcinoma, and advanced triple negative breast cancer, will be presented at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29 - June 2 in Chicago, Illinois, US).
AB: 26.72 (-0.07)
AB Science: Masitinib Treatment of Advanced Pancreatic Cancer, publication of Phase III Results in Annals of Oncology
GlobeNewswire - Thu Apr 09, 11:25AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of results from the first randomized phase 3 study of masitinib in treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Entitled, 'A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer' this article and its accompanying Online Supplementary Material are freely accessible online from the peer-reviewed journal Annals of Oncology: http://annonc.oxfordjournals.org/lookup/doi/1...onc/mdv133. A phase 3 confirmatory study is currently ongoing.
AB: 26.72 (-0.07), LLY: 86.14 (+2.37)
AB Science: Masitinib Receives Orphan Drug Designation for Amyotrophic Lateral Sclerosis from FDA
GlobeNewswire - Fri Mar 20, 1:32PM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug designation for masitinib in the treatment of amyotrophic lateral sclerosis.
AB: 26.72 (-0.07)
AB Science: Positive Phase 2 Clinical Study Data of Masitinib in Second-Line Metastatic Stomach Cancer
GlobeNewswire - Mon Feb 02, 11:26AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announced encouraging efficacy and safety results from a phase 2 study with its investigational drug, masitinib, in patients with nonresectable, metastatic esophagogastric adenocarcinoma after progression to first-line treatment.
AB: 26.72 (-0.07)
AB Science: The Data and Safety Monitoring Board Recommends the Continuation of Phase 3 Study of Masitinib in Amyotrophic Lateral Sclerosis
GlobeNewswire - Tue Jan 13, 10:48AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the external Data and Safety Monitoring Board (DSMB) has recommended the continuation of its phase 3 study of masitinib in amyotrophic lateral sclerosis (ALS) based upon review of the latest safety data. The DSMB was created as part of the Company's pivotal clinical study evaluating masitinib in the treatment of amyotrophic lateral sclerosis.
AB: 26.72 (-0.07)
AB Science advances Ultra-Selective SYK Kinase Inhibitor into Full Preclinical Development
GlobeNewswire - Fri Nov 28, 10:58AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), reported the advancement of a novel, small molecule SYK kinase inhibitor named AB8779 into full preclinical development.
AB: 26.72 (-0.07)
AB Science: Web conference on masitinib in asthma - Safety and Efficacy Update
GlobeNewswire - Tue Nov 25, 10:55AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), is hosting a web conference on masitinib in the treatment of asthma with key opinion leaders from this disease.
AB: 26.72 (-0.07)
AB Science: The Data and Safety Monitoring Board recommends the continuation of the phase 2 study with masitinib in advanced hepatocellular carcinoma
GlobeNewswire - Wed Nov 12, 10:50AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the external Data and Safety Monitoring Board (DSMB) has recommended the continuation of its phase 2 study of masitinib in advanced hepatocellular carcinoma based upon review of the latest safety and efficacy data. The DSMB was created as part of the Company's clinical study evaluating masitinib in the treatment of advanced hepatocellular carcinoma.
AB: 26.72 (-0.07)
AB Science : Web conference on Masitinib in mastocytosis
GlobeNewswire - Fri Oct 31, 11:52AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), is hosting a web conference on masitinib in the treatment of mastocytosis with key opinion leaders from this disease.
AB: 26.72 (-0.07)
Global B-Cell Chronic Lymphocytic Leukemia Pipeline Review, H2 2015 - 21 Companies & 31 Drug Profiles
M2 - Wed Oct 07, 3:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jtsp4f/bcell_chronic) has announced the addition of the "B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - AbbVie Inc. - Advancell - Amgen Inc. - BioNovion B.V. - Celgene Corporation - Dynavax Technologies Corporation - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Formula Pharmaceuticals, Inc. - iDD biotech SAS - Immunomedics, Inc. - Johnson & Johnson - Juno Therapeutics Inc. - Nippon Shinyaku Co., Ltd. - Noxxon Pharma AG - Ono Pharmaceutical Co., Ltd. - Regeneron Pharmaceuticals, Inc. - SBI Biotech Co., Ltd. - TheraMAB LLC - Vivia Biotech, S.L. Drug Profiles - 202-b - AB-8779 - acadesine - alemtuzumab biosimilar - AMG-319 - bafetinib - BION-1301 - Cell Therapy for Hematological Malignancies - Cell Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Cell Therapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Cell Therapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Cell Therapy to Target CD16 for CLL and NHL - Cell Therapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Cell Therapy to Target CD19 for Cancer - Cell Therapy to Target CD19 for Oncology - Cell Therapy to Target CD23 for B-Cell Chronic Lymphocytic Leukemia - E-7449 - GNKS-356 - IDD-001 - IDD-002 - ilorasertib - JNJ-64052781 - lenalidomide - MAT-303 - olaptesed pegol - ONO-4059 - REGN-1979 - SD-101 - TAB-08 - tocilizumab - Vivia-009 For more information visit http://www.researchandmarkets.com/research/jt...ll_chronic
DVAX: 23.86 (+0.39), JNJ: 95.37 (+0.29), IMMU: 2.17 (+0.12), AMGN: 149.59 (-0.31), JUNO: 48.64 (+0.84), ABBV: 55.64 (-0.40), REGN: 503.92 (+12.71), CELGZ: 1.74 (+0.04)
Gastric Cancer - Pipeline Review, H2 2015 Featuring Over 100 Companies
M2 - Mon Oct 05, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lhb64g/gastric_cancer) has announced the addition of the "Gastric Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - 30 of the 100 Companies - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Azaya Therapeutics Incorporated - Basilea Pharmaceutica AG - Bayer AG - BioMarin Pharmaceutical Inc. - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - cCAM Biotherapeutics Ltd. - Celgene Corporation - Celldex Therapeutics, Inc. - Cellectar Biosciences, Inc. - Celltrion, Inc. - Celon Pharma Sp. z o.o. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Chugai Pharmaceutical Co., Ltd. - Curaxys, S.L. For more information visit http://www.researchandmarkets.com/research/lh...ric_cancer
CLRB: 2.01 (+0.03), ADXS: 11.07 (+0.83), BMRN: 102.69 (+1.97), CERU: 3.65 (+0.07), AMBX: (), CLDX: 12.80 (+1.06), AMGN: 149.59 (-0.31), BMY: 61.44 (+0.93), AZN: 32.23 (-0.16), AVEO: 1.27 (+0.05), ABBV: 55.64 (-0.40), CELGZ: 1.74 (+0.04)
Global Germ Cell Tumors Pipeline Review H2 2015 - 8 Companies & 11 Drug Profiles
M2 - Mon Oct 05, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/444kf4/germ_cell_tumors) has announced the addition of the "Germ Cell Tumors - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Germ Cell Tumors, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Germ Cell Tumors and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - ArQule, Inc. - Astex Pharmaceuticals, Inc. - GlaxoSmithKline Plc - MediGene AG - Merck & Co., Inc. - Novartis AG - Philogen S.p.A. - Sanofi Drug Profiles - cabazitaxel - Cell Therapy 1 for Oncology - (dabrafenib mesylate trametinib dimethyl sulfoxide) - G-207 - guadecitabine - pembrolizumab - ribociclib - Small Molecule to Antagonize KIT816 for Aggressive Mastocytosis, Seminoma and AML - Small Molecules to Inhibit Tubulin for Oncology - Tetravil - tivantinib For more information visit http://www.researchandmarkets.com/research/44...ell_tumors
MRK: 50.95 (-0.07), ARQL: 2.04 (+0.05), GSK: 40.22 (+0.06), NVS: 91.90 (-0.71)
AB Science announces cessation of its rheumatoid arthritis study in order to focus on clinical studies with a probability of success greater than 50%
GlobeNewswire - Mon Sep 21, 11:07AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces today the decision to stop the phase 3 study of masitinib in rheumatoid arthritis in order to streamline its studies portfolio. This decision has been made following a futility test, conducted by the external Data and Safety Monitoring Board (DSMB), showing that the probability of success on the primary endpoint was below 50% for this study, including the resampling option.
AB: 26.72 (-0.07)
AB Science: Masitinib Receives Orphan Drug Designation for Stomach Cancer from FDA
GlobeNewswire - Wed Sep 16, 11:07AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug designation for masitinib in the treatment of esophagogastric adenocarcinoma.
AB: 26.72 (-0.07)
Global Secondary Progressive Multiple Sclerosis (SPMS) Pipeline Review, H2 2015 - 12 Companies & 17 Drug Profiles
M2 - Tue Sep 08, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j7vt6v/secondary) has announced the addition of the "Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - Biogen, Inc. - Daval International Limited - Genzyme Corporation - Glialogix, Inc. - Immune Response BioPharma, Inc. - Innate Immunotherapeutics Limited - Kyorin Pharmaceutical Co., Ltd. - MedDay - Merck KGaA - Novartis AG - Opexa Therapeutics, Inc. Drug Profiles - Aimspro - ApE - ATXMS-1467 - biotin - DC-TAB - GLX-1112 - GZ-402668 - ibudilast - imilecleucel-t - interferon beta-1b - IR-902 - masitinib - MIS-416 - natalizumab - opicinumab - OSX-110 - siponimod For more information visit http://www.researchandmarkets.com/research/j7vt6v/secondary
OPXA: 3.20 (-0.08), NVS: 91.90 (-0.71)
AB Science announces successful futility test for masitinib in c-Kit mutated metastatic melanoma
GlobeNewswire - Tue Jul 21, 11:32AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), today announced the successful non futility analysis related to the masitinib phase 3 trial in metastatic melanoma, carrying a mutation in the juxta membrane domain of c-Kit. Based on these results, the Independent Data Safety Monitoring Committee (IDMC) has recommended continuation of the study.
AB: 26.72 (-0.07)
AB Science announces initiation of an adaptive design phase 2/3 study with masitinib in patients with refractory metastatic ovarian cancer
GlobeNewswire - Wed Jul 15, 11:12AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the initiation of a seamless adaptive design phase 2/3 study to evaluate the safety and efficacy of masitinib in combination with gemcitabine in patients with refractory advanced or metastatic epithelial ovarian cancer.
AB: 26.72 (-0.07)
AB Science: the Data and Safety Monitoring Board recommends continuation of three phase 2 studies
GlobeNewswire - Thu Jul 02, 11:21AM CDT
The Data and Safety Monitoring Board recommends continuation of three phase 2 studies assessing masitinib in relapsing liver cancer, breast cancer, and head and neck cancer based on safety and efficacy data
AB: 26.72 (-0.07)
AB Science: Update on phase 1/2 program with masitinib in solid tumors
GlobeNewswire - Thu Jun 25, 12:52PM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), presents an update of its masitinib phase 1/2 program in solid tumors.
AB: 26.72 (-0.07)
AB Science: Independent Publication from experts highlights the potential of masitinib in Alzheimer's disease
GlobeNewswire - Thu May 21, 12:56PM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announces the publication of a wide-ranging independent review article entitled 'Masitinib for the treatment of mild to moderate Alzheimer's disease' in the peer-reviewed journal Expert Review of Neurotherapeutics.
AB: 26.72 (-0.07)
AB Science announces that three clinical abstracts will be presented at the 2015 ASCO annual meeting
GlobeNewswire - Mon May 18, 11:43AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announced that the three abstracts reporting on phase 2 studies of masitinib in metastatic colorectal cancer, metastatic esophagogastric adenocarcinoma, and advanced triple negative breast cancer, will be presented at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29 - June 2 in Chicago, Illinois, US).
AB: 26.72 (-0.07)
AB Science: Masitinib Treatment of Advanced Pancreatic Cancer, publication of Phase III Results in Annals of Oncology
GlobeNewswire - Thu Apr 09, 11:25AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of results from the first randomized phase 3 study of masitinib in treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Entitled, 'A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer' this article and its accompanying Online Supplementary Material are freely accessible online from the peer-reviewed journal Annals of Oncology: http://annonc.oxfordjournals.org/lookup/doi/1...onc/mdv133. A phase 3 confirmatory study is currently ongoing.
AB: 26.72 (-0.07), LLY: 86.14 (+2.37)
AB Science: Masitinib Receives Orphan Drug Designation for Amyotrophic Lateral Sclerosis from FDA
GlobeNewswire - Fri Mar 20, 1:32PM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug designation for masitinib in the treatment of amyotrophic lateral sclerosis.
AB: 26.72 (-0.07)
AB Science: Positive Phase 2 Clinical Study Data of Masitinib in Second-Line Metastatic Stomach Cancer
GlobeNewswire - Mon Feb 02, 11:26AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announced encouraging efficacy and safety results from a phase 2 study with its investigational drug, masitinib, in patients with nonresectable, metastatic esophagogastric adenocarcinoma after progression to first-line treatment.
AB: 26.72 (-0.07)
AB Science: The Data and Safety Monitoring Board Recommends the Continuation of Phase 3 Study of Masitinib in Amyotrophic Lateral Sclerosis
GlobeNewswire - Tue Jan 13, 10:48AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the external Data and Safety Monitoring Board (DSMB) has recommended the continuation of its phase 3 study of masitinib in amyotrophic lateral sclerosis (ALS) based upon review of the latest safety data. The DSMB was created as part of the Company's pivotal clinical study evaluating masitinib in the treatment of amyotrophic lateral sclerosis.
AB: 26.72 (-0.07)
AB Science advances Ultra-Selective SYK Kinase Inhibitor into Full Preclinical Development
GlobeNewswire - Fri Nov 28, 10:58AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), reported the advancement of a novel, small molecule SYK kinase inhibitor named AB8779 into full preclinical development.
AB: 26.72 (-0.07)
AB Science: Web conference on masitinib in asthma - Safety and Efficacy Update
GlobeNewswire - Tue Nov 25, 10:55AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), is hosting a web conference on masitinib in the treatment of asthma with key opinion leaders from this disease.
AB: 26.72 (-0.07)
AB Science: The Data and Safety Monitoring Board recommends the continuation of the phase 2 study with masitinib in advanced hepatocellular carcinoma
GlobeNewswire - Wed Nov 12, 10:50AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the external Data and Safety Monitoring Board (DSMB) has recommended the continuation of its phase 2 study of masitinib in advanced hepatocellular carcinoma based upon review of the latest safety and efficacy data. The DSMB was created as part of the Company's clinical study evaluating masitinib in the treatment of advanced hepatocellular carcinoma.
AB: 26.72 (-0.07)
AB Science : Web conference on Masitinib in mastocytosis
GlobeNewswire - Fri Oct 31, 11:52AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), is hosting a web conference on masitinib in the treatment of mastocytosis with key opinion leaders from this disease.
AB: 26.72 (-0.07)
